Bioadaptives, Inc. financial data

Symbol
BDPT on OTC
Industry
Pharmaceutical Preparations
Location
2620 Regatta Drive, Suite 102, Las Vegas, NV
State of incorporation
DE
Fiscal year end
December 31
Former names
APEX 8 Inc. (to 8/19/2013)
Latest financial report
10-Q - Q3 2024 - Nov 19, 2024

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 2.49 % -37.9%
Quick Ratio 0.54 % +25.5%
Debt-to-equity -104 % +3.2%
Return On Equity 44.7 % +39.8%
Return On Assets -1.46K % -231%
Operating Margin -1.64K %

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 1.23B shares
Common Stock, Shares, Outstanding 1.23B shares +58.6%
Entity Public Float 358K USD
Common Stock, Value, Issued 123K USD +58.6%
Weighted Average Number of Shares Outstanding, Basic 896M shares +22.7%

Income Statement

Label TTM Value / Value Unit Change %
Revenues 19.9K USD -21.6%
Cost of Revenue 13.1K USD -18.9%
General and Administrative Expense 118K USD +51.8%
Operating Income (Loss) -327K USD -32.2%
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest -367K USD +25.4%
Net Income (Loss) Attributable to Parent -796K USD -68.4%
Earnings Per Share, Basic 0 USD/shares

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 60.8K USD -26.7%
Marketable Securities, Current 0 USD -100%
Inventory, Net 0 USD -100%
Assets, Current 46.4K USD -71.5%
Intangible Assets, Net (Excluding Goodwill) 18K USD
Assets 46.4K USD -85.9%
Accounts Payable, Current 3.34K USD -37.4%
Accrued Liabilities, Current 162K USD +28.4%
Liabilities, Current 1.85M USD +25.5%
Liabilities 1.85M USD +25.5%
Retained Earnings (Accumulated Deficit) -8.79M USD -9.95%
Stockholders' Equity Attributable to Parent -1.81M USD -57.6%
Liabilities and Equity 46.4K USD -85.9%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -41.2K USD -112%
Net Cash Provided by (Used in) Financing Activities 0 USD -100%
Common Stock, Shares Authorized 1.25B shares 0%
Common Stock, Shares, Issued 1.23B shares +58.6%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect -27.1K USD -238%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 43.9K USD -71.1%
Interest Paid, Excluding Capitalized Interest, Operating Activities 0 USD
Deferred Tax Assets, Valuation Allowance 585K USD +11.4%
Deferred Tax Assets, Operating Loss Carryforwards 585K USD +11.4%
Preferred Stock, Shares Authorized 10M shares 0%
Additional Paid in Capital 6.86M USD +1.33%
Amortization of Intangible Assets 9.13K USD -77%
Deferred Tax Assets, Net of Valuation Allowance 0 USD
Interest Expense 121K USD -43.2%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%